Member Info for bigAl67

@Prof SPD,

Thanks for the Compliment LOL

Actually - All the Sums come from Publications, for All to find !!! - I just put the Maths together !!!

Have a NICE Day LOL

My pleasure onlyprofit !!!

Volume 1,636,059

Vol. Sold 776,131

Vol. Bought 959,928

Our Funding well into 2025 is looking Good - My post yesterday is coming together well !!!

As of 14th March 2023 we had £2 mil in cash + £2 Mil from RF in April + No less than £500k R&D Tax refund due end of this year 2023 = £4,500,000

Since April we have also received a further £600,000 from RF (And a further £336,000 is due from RF on exercise of their first two drawdowns of Warrants – Date unknown?)

So £4,500,000 + £600,000 (Drawdown money from RF) = £5,100,000

Should we receive £2,100,000 DEVOTE Funding then we are looking at £7,200,000, which takes Our Financial status forward 18 Months Funding from March 14th 2023 = 14th September 2024.

Note: - Although DEVOTE funding of £2,100,000 may not be paid to Our Genedrive in a cash lump sum - it would reduce Our monthly outgoing £400k costs, which I believe may be already reducing our CYP2C19 development costs by as much as £125,000 per month. This saving is effectively keeping cash in the bank!!

Then - If we conservatively add in a further £1,000,000 Tax Development Refund for the period Jan 2023 to end of June 2024 – Takes Our Finances to £8,200,000 = 30th November 2024.

I believe we will receive a further £2,400,000 Drawdown money (8 x £300,000) from RF – Should this be so - Then we are looking at Funding well into 2025 !!

Along this Financial road, we will be receiving revenue from AIHL and CYP2C19 sales - to add in !!!

From Our GDR - DEVOTE Funding - ‘’to further the ‘validation’ and ‘implementation’ of the new Genedrive® CYP2C19 ID Kit pharmacogenetic test in a time critical clinical setting’’ = ‘'Validation’ and ‘Implementation’'

AIMVHO !!!

Oh Dear - Calm down Slacker - You come across a Tad Stressed chap - LOL

''Why would Our SP go Up with a Sell'',..... Answer = When the sell is followed by a Buy = 100,000 shares sold at 10.25p, and Our SP went up to 10.50p, with the 42,000 share Buy that followed the 100,000 sell !!! LOL

BTW - Nissan did not say that our SP went up because of the 100,000 sell - he just pointed out that he is surprised Our SP didn't hit over 11p '''today''' - LOL

Maybe because:-

Vol. Sold 252,099

Sold Value £26.00k

Vol. Bought 981,385

Bought Value £96.43k

Hope this helps to Calm your Stress Chap !!

Simple - followed by a 42,000 share Buy - LOL

Good morning onlyprofit,

For your consideration:-

As of 14th March 2023 we had £2 mil in cash + £2 Mil from RF in April + No less than £500k R&D Tax refund due end of this year 2023 = £4,500,000

Since April we have also received a further £600,000 from RF (And a further £336,000 is due from RF on exercise of their first two drawdowns of Warrants – Date unknown?)

So £4,500,000 + £600,000 (Drawdown money from RF) = £5,100,000

Should we receive £2,100,000 DEVOTE Funding then we are looking at £7,200,000, which takes Our Financial status forward 18 Months Funding from March 14th 2023 = 14th September 2024.

Note: - Although DEVOTE funding of £2,100,000 may not be paid to Our Genedrive in a cash lump sum - it would reduce Our monthly outgoing £400k costs, which I believe may be already reducing our CYP2C19 development costs by as much as £125,000 per month. This saving is effectively keeping cash in the bank!!

Then - If we conservatively add in a further £1,000,000 Tax Development Refund for the period Jan 2023 to end of June 2024 – Takes Our Finances to £8,200,000 = 30th November 2024.

I believe we will receive a further £2,400,000 Drawdown money (8 x £300,000) from RF – Should this be so - Then we are looking at Funding well into 2025 !!

Along this Financial road, we will be receiving revenue from AIHL and CYP2C19 sales - to add in !!!

From Our GDR - DEVOTE Funding - ‘’to further the ‘validation’ and ‘implementation’ of the new Genedrive® CYP2C19 ID Kit pharmacogenetic test in a time critical clinical setting’’ = ‘'Validation’ and ‘Implementation’'

AIMVHO !!!

That Slacker fellow keeps referring to our UKCA Approval as a UKSA Sticker - He obviously knows nothing about Our GDR and Our Approvals LOL !!!!

UKSA - United Kingdom Sailing Academy - Cowes, Isle of Wight

About time he took his UKSA Sticker and Sail Away - He does come over as a TAD Desperate !!!! LOL

We can Now sell our CYP2C19 in the UK (England; Scotland and Wales) !!!

The UKCA marking must be used for placing goods on the market in Great Britain from 1 January 2023. The UKCA marking can be used now and we encourage businesses to start using the UKCA marking as soon as possible.

Great find JLC, - Agreed stephen11 - Looking Good !!

As of 14th March 2023 we had £2 mil in cash + £2 Mil from RF in April + No less than £500k R&D Tax refund due end of this year.=. £4,500,000

Since April we have also received a further £600,000 from RF (And a further £336,000 due from RF on exercise of their first two drawdowns of Warrants – Date unknown?)

So £4,500,000 + £600,000 (Drawdown money from RF) = £5,100,000

Add in £2,100,000 DEVOTE Funding then we are looking at £7,200,000 = 18 Months Funding from March 14th 2023 = 14th September 2024.

DEVOTE Funding - ‘’to further the ‘validation’ and ‘implementation’ of the new Genedrive® CYP2C19 ID Kit pharmacogenetic test in a time critical clinical setting’’ - ‘'Validation’ and ‘Implementation’'

Should we receive a further £2,400,000 Drawdown money (8 x £300,000) from RF - Then we are looking at Funding until March 14th 2025 !!

Then - If we conservatively add in a further £1,000,000 Tax Development Refund for the period Jan 2023 to end of June 2024.

Rushing to go out for the evening, and I know there is Funding notes I have not listed !!! LOL

@Dodgy Rog,

Reference:- ''This is scary. It’s like living in a parallel universe.

From the half year report RNS - Cash of £2.0m on 14 March 2023 following recent receipt of R&D tax credit of £0.96m

So with the £2m from RF and a further £600k via 2 drawdowns that’s it.''

Well done on understanding the first Part of the Half Year report, which is the £2,000,000 cash as of the 14th March, Then plus the £2,000,000 from RF, plus the further £600,000 - drawdowns from RF = £4,600,000 !!

However, You are wrong again - This time with Your ''that's it''

Now I am Happy to guide You through this, one small step at a time - as I recognise You are not Sufficiently Competent to understand too much information in one go ?!!

So Step 1 of Your Learning process - If you drill down through the Half Year Report to Item 6 - You will see the following report:-

6. Current tax asset

The current tax asset relates to tax owing under the R&D tax credit scheme of £1,456k (2021: £1,666k). A payment of £956k was received in March 2023. The remaining £500k is an estimate of the tax credit for the interim period to December 2022 and this £500k will be received following submission of the tax returns for the 12 months to June 2023, with receipt expected to be before 31 December 2023.

Hopefully You will understand that the Tax refund of ''£956k received in March 2023'', is part of the Total Tax refund credit of £1,456k - which means a further £500,000 Tax credit is expected receipt before the end of this current year December 31st 2023. !!

OK, so now add this £500,000 to the above Total and we arrive at a cash sum of £5,100,000 (You should recognise this cash amount in the Maths Post I posted earlier today!!

Now once You recognise You missed this £500,000 credit, let me know, and I will take You through the next step of Your learning !!

This will take some time to complete, however, I believe the benefits of Your leaning is well worth the time?!!

Hi stephen11,

Agreed the Non-Shareholding Trolls Team together Slinging their Non-Shareholding CA*P, without Any True Research - They are Neither Capable, Nor Worthy !! QED

Hi JLC,

Agreed, - Genedrive have clearly stated that the Company.s cash resources will be directed towards our AIHL and CYP2C19 Tests - Genedrive does not say any of the cash will be spent on any ''other'' future Development Tests :-

From the RNS Number : 0323V

Genedrive PLC

31 March 2023

The Facility and the Company's existing cash resources will be directed towards the commercialisation of the Company's Antibiotic Induced Hearing Loss test, Genedrive® MT-RNR1 ID Kit ("AIHL test") and enhancing the Genedrive® platform through the validation and verification of the Company's CYP2C19 test, Genedrive® CYP2C19 ID Kit ("CYP2C19 test") as well as providing additional working capital.

The Non-Shareholder - Dodgey Rog is obviously the person who does not understand ''simple statements'' - No surprise here LOL !!!

No counter financial calculations from the Non-Shareholding Team of Trolls - Just Dodgey assumptions - LOL - I really believe they are ''Completely Un-educated and Clueless'' !!! IMVHO

Maths for GDR Financial Position, As I see it:-

As of 14th March 2023 we had £2 mil in cash + £2 Mil from RF in April + No less than £500k R&D Tax refund due end of this year.=. £4,500,000

Since April we have also received a further £600,000 from RF (And a further £336,000 due from RF on exercise of their first two drawdowns of Warrants – Date unknown?)

So £4,500,000 + £600,000 (Drawdown money from RF) = £5,100,000 - This alone takes us to September 2024 at Monthly Expenditure of £275,000 - see DEVOTE Funding adjustment below:

Should we receive a further £2,400,000 Drawdown money (8 x £300,000) from RF -

Then £5,100,000 + £2,400,000 = £7,500,000

If we conservatively add in a further £1,000,000 Tax Development Refund for the period Jan 2023 to end of June 2024.

Then our Total cash increases from £7,500,000 to £8,500,000

Then we have Funding from DEVOTE – ‘’to further the ‘validation’ and ‘implementation’ of the new Genedrive® CYP2C19 ID Kit pharmacogenetic test in a time critical clinical setting’’.– saving us our current CYP2C19 Development spend of £125,000 per month – and reducing our cash runaway from £400k to £275k per month !!.

£8,500,000 divided by £275,000 = 31 Months, which takes us from 14th March 2023 to Mid - October 2025.

Then it depends upon Sales Revenue from the UK and Europe; also further Funding from DEVOTE, and

Any Other Funding we receive over this time period.

All going well - Finances Look OK to me !!!

@Gloria,

Out of interest - When did you sell out of GDR - Was it today? - A few days ago? - A few weeks ago? Or was it Months ago?

Hi stephen11,

Agreed, I also had my suspicions from the start of 'saintstock' posts, just wanted further evidence before I posted IMVHO.

Not only did I expect 'saintstock' to build on his not so subtle negative posts towards GDR, but I also expected 'saintstock' to start posting on the Lon: Bur BB, which he/she has done.

'saintstock' appeared on our GDR BB on the same/next day that 'starresnstoff' was banned by the LSE, and 'saintstock' immediately posted in the same negative manner towards GDR, as 'starresnstoff' had - one for LSE to look into?

If anyone is still unsure as to whether 'saintstock' is actually the LSE Banned 'starresnstoff' - reincarnated, - then click on 'saintstock' posting name and check out his posts - you will see that 'saintstock' is now posting, on the Burford Capital BB (Lon: Bur) too.

Burford Capital is the company that 'starresnstoff' stated he had invested 'All In', when he totally sold 'All out' from GDR - QED?

'starresnstoff' stated that he is Bitter towards GDR, because he only made a 6% profit from his total investment in GDR.

The LSE Banned 'starresnstoff', and closed All of 'starresnstoff' posts - This is not an action that the LSE take lightly.

Nice to see a 100,000 share Buy at the close - Shame our SP did not close up - hopefully tomorrow !!

Recent Share Trades for Genedrive (GDR)

Date Time Trade Prc Volume Buy/Sell Bid Ask Value

21-Aug-23 17:06:52 12.00 4,500 Unknown* 11.50 12.50 540.00 O

21-Aug-23 16:30:03 12.00 100,000 Unknown* 11.50 12.50 12.00k O

21-Aug-23 14:57:24 11.65 168 Sell* 11.50 12.50 19.57 O

21-Aug-23 14:47:25 12.29 3,972 Buy* 11.50 12.50 488.16 O

21-Aug-23 14:42:26 12.26 56,990 Buy* 11.50 12.50 6,987

Great to know you are well System !!

So Dodgy Roger - The Non - GDR Shareholder Troll is right, and this Dodgy character wants us to believe the LSE is wrong in their report that states ''There are currently no open short positions in Genedrive.'' LOL - How desperate and how Low will these Trolls go ???

Once again NO Evidence that he is telling the Truth - Just believe him that ''The LSE are Notoriously wrong'' - unless they are showing that there ''are Shorts positions held'' eg:- Dodgy Rog states - ''I wonder if GSA Capital Partners increased their short here? They were at .48% mid Jan'' - It would not fit Dodgy Rog's agenda for the LSE to be wrong about this - WOW - QED Rog QED !!!